Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Rapid-Infusion Isatuximab in RRMM
NCT04802031Phase 2Withdrawn
- Start
- May 2021
- Primary completion
- Nov 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of isatuximab in multiple myeloma (MM). Primary endpoint: Incidence of grade 2 or higher infusion-related reactions at 6 months. Planned start May 2021; status: withdrawn.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04802031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04802031.